Literature DB >> 8979563

Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study.

N Thilothammal1, K Banu, R S Ratnam.   

Abstract

OBJECTIVE: To compare the efficacy and side effects of phenobarbitone (PB), phenytoin (PHT) and sodium valproate (SVP) in controlling generalized tonic-clonic convulsions (GTC).
DESIGN: Randomized, double blind clinical trial.
SETTING: Out-Patients in a tertiary care hospital. PATIENTS: 151 children with GTC, aged 4-12 yrs, from Madras city were enrolled. At the end of 2 yrs, 127 children remained in the study. INTERVENTION: Each child was given one active drug and 2 placebo tablets. Clinical, hematological and biochemical evaluations were done every month. Serum drug levels were assessed periodically. MAIN OUTCOME MEASURES: Recurrence of convulsion and side effects.
RESULTS: The proportion of children with recurrence did not differ among the 3 groups. More than one side effect was observed in 16 (32%) children on PB, 20 (40%) children on PHT and 9 (19%) children on SVP and this difference was statistically significant (p < 0.05). Hyperactivity was the major side effect of PB, observed in 22% of children.
CONCLUSION: All 3 drugs were equally effective in controlling seizures. Side effects were minimal with SVP followed by PB. Though side effects were more frequent with PHT, most of them disappeared on adjusting drug dosage. Least expensive phenobarbitone may be preferred as the first drug of choice but, only for pre-school children. SVP is advised for school going children.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8979563

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  16 in total

Review 1.  Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-07-31

Review 2.  Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

Authors:  Sarah J Nevitt; Maria Sudell; Jennifer Weston; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2017-06-29

Review 3.  Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures.

Authors:  S Taylor; C Tudur Smith; P R Williamson; A G Marson
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 4.  Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations.

Authors:  John Piedad; Hugh Rickards; Frank M C Besag; Andrea E Cavanna
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

Review 5.  Valproate as a mainstay of therapy for pediatric epilepsy.

Authors:  Renzo Guerrini
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Proposed guidelines for the management of nodding syndrome.

Authors:  R Idro; K A Musubire; B Byamah Mutamba; H Namusoke; J Muron; C Abbo; R Oriyabuzu; J Ssekyewa; C Okot; D Mwaka; P Ssebadduka; I Makumbi; B Opar; J R Aceng; A K Mbonye
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

Review 7.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review.

Authors:  Sarah J Nolan; Anthony G Marson; Jennifer Weston; Catrin Tudur Smith
Journal:  Cochrane Database Syst Rev       Date:  2016-04-28

Review 9.  Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy.

Authors:  Victor Biton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 10.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.

Authors:  Kevin G Bath; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-08       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.